BACKGROUND: The survival benefit of surveillance for hepatocellular carcinoma (HCC) is controversial. AIM: We aimed to examine the survival benefit of HCC surveillance in chronic viral hepatitis. METHODS: Survivals of HCC patients related to chronic viral hepatitis from the Hepatology Clinic (surveillance group) were compared with those referred from other hospitals/clinics (no-surveillance group). Lead-time and length-time biases were adjusted based on tumour volume doubling times. RESULTS: Among 579 patients (91% hepatitis B), 472 (82%) patients had HCC and 79 (17%) of these patients were referred from the surveillance programme. HCC was smaller (4.2 vs. 7.7 cm; P<0.001) and fewer in numbers (2.6 vs. 3.8, P=0.03) in the surveillance group vs. the no-surveillance group. Treatment by surgery (20 vs. 10%, P=0.007) and local ablative therapy (46 vs. 19%, P<0.001) were more frequent in the surveillance group than that in the no-surveillance group. The median survival of the surveillance group (88 weeks) was significantly longer than that of the no-surveillance group (26 weeks) (P<0.001). The adjusted cumulative survival at 2 years was significantly longer in the surveillance group if the tumour volume doubling time was <90 days (P=0.0352). CONCLUSIONS: HCC surveillance can improve the survival of patients with chronic viral hepatitis B.
BACKGROUND: The survival benefit of surveillance for hepatocellular carcinoma (HCC) is controversial. AIM: We aimed to examine the survival benefit of HCC surveillance in chronic viral hepatitis. METHODS: Survivals of HCC patients related to chronic viral hepatitis from the Hepatology Clinic (surveillance group) were compared with those referred from other hospitals/clinics (no-surveillance group). Lead-time and length-time biases were adjusted based on tumour volume doubling times. RESULTS: Among 579 patients (91% hepatitis B), 472 (82%) patients had HCC and 79 (17%) of these patients were referred from the surveillance programme. HCC was smaller (4.2 vs. 7.7 cm; P<0.001) and fewer in numbers (2.6 vs. 3.8, P=0.03) in the surveillance group vs. the no-surveillance group. Treatment by surgery (20 vs. 10%, P=0.007) and local ablative therapy (46 vs. 19%, P<0.001) were more frequent in the surveillance group than that in the no-surveillance group. The median survival of the surveillance group (88 weeks) was significantly longer than that of the no-surveillance group (26 weeks) (P<0.001). The adjusted cumulative survival at 2 years was significantly longer in the surveillance group if the tumour volume doubling time was <90 days (P=0.0352). CONCLUSIONS: HCC surveillance can improve the survival of patients with chronic viral hepatitis B.
Authors: Sahil Mittal; Fasiha Kanwal; Jun Ying; Randy Chung; Yvonne H Sada; Sarah Temple; Jessica A Davila; Hashem B El-Serag Journal: J Hepatol Date: 2016-07-29 Impact factor: 25.083